Booming New Drug Sector Can’t Hide Weakness in Medical Devices: Slowing Medical Device Growth Drags Down Johnson & Johnson (JNJ.US) Q2 Strong Earnings
智通财经2026/07/16 13:06Zhitong Finance APP reports that, thanks to the strong growth in drugs for treating cancer, inflammatory diseases, and treatment-resistant depression, Johnson & Johnson (JNJ.US) exceeded expectations in its second-quarter sales. The financial report shows that Johnson & Johnson's Q2 revenue reached $25.31 billion, an increase of 6.6% year-on-year, surpassing expectations by $250 million; non-GAAP earnings per share were $2.90, $0.05 above expectations.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
10-year US Treasury yields approach 5%, US stocks pull back: Goldman Sachs remains bullish against the trend—an “insurance-rate hike” or the restart of the tightening cycle?
This week, the biggest suspense in the Federal Reserve meeting may no longer be whether there will be a rate hike.
Australian Dollar declines to near 0.7150 as hot US inflation data boost case for Fed rate hike
The AI super bull market still has room for imagination, but Wall Street has quietly prepared "two types of insurance": to guard against slow declines eroding returns, as well as to protect from sudden crashes.
Due to rising interest rates and oil prices causing the stock market rally to stall, investors are divided—some worry about a rapid sell-off, while others are concerned about a slow market decline. Some traders have become more creative with bearish strategies, such as buying put options on the Chicago Board Options Exchange Volatility Index or the S&P 500, or using double binary options to bet on a gradual price drop.
Crypto prices
More
